Vaxcyte, Inc. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-06-07

Reporting Person: Fairman Jeff (VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-07	Common Stock	M	7259	$0.04	Acquired	12403	Direct
2021-06-07	Common Stock	M	2241	$1.79	Acquired	14644	Direct
2021-06-07	Common Stock	S	9500	$22.50	Disposed	5144	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-07	Stock Option (right to buy)	$0.04	M	7259	Disposed	2025-04-23	Common Stock (7259)	Direct
2021-06-07	Stock Option (right to buy)	$1.79	M	2241	Disposed	2027-05-17	Common Stock (2241)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	341227	Indirect
Common Stock	50000	Indirect

Footnotes

F1: Includes 943 shares acquired under the Employee Stock Purchase Plan on May 17, 2021.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: The shares subject to the option are fully vested and exercisable.

F4: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48th of the shares vest monthly thereafter.